Skip to main content
Persistent Corneal Epithelial DefectVision and hearingDrugPhase 2

What this study is

In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.

What's being tested

  • Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome

    Intervention · DRUG

  • Vehicle Control

    Intervention · OTHER

Both interventions

Eye Drops

Study details

Official title
Phase II Study of the Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Sponsor
University of Illinois at Chicago
Conditions
Persistent Corneal Epithelial Defect · Corneal Epithelial Disorders
Enrolling
24 people
Starts
2025-08-01
Est. completion
2026-12-15
Design
Double-blind, randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗